A study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD6234 after repeat dose administration in participants who are overweight or obese

Study identifier:D8750C00002

ClinicalTrials.gov identifier:NCT06132841

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase I Randomized, Single-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD6234 Following Repeat Dose Administration in Participants with Overweight or Obesity

Medical condition

Healthy Participants

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6234, Placebo

Sex

All

Estimated Enrollment

76

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 13 Nov 2023
Estimated Primary Completion Date: 30 Apr 2025
Estimated Study Completion Date: 30 Apr 2025

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria